15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
15:23 , Apr 13, 2018 |  BC Week In Review  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...
15:48 , Apr 12, 2018 |  BC Extra  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...
18:09 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports early Phase I/II liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said its NY-ESO SPEAR T cell therapy led to three partial responses and one case of stable disease in the first four patients with myxoid/round cell liposarcoma (MRCLS) in an open-label,...
21:03 , Mar 15, 2018 |  BC Extra  |  Clinical News

Adaptimmune gains on early liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $1.73 (19%) to $10.94 on Thursday after reporting that its NY-ESO SPEAR T cell therapy led to three partial responses and one case of stable disease in the first four...
19:25 , Sep 8, 2017 |  BC Week In Review  |  Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune was preparing for a pivotal trial...
00:23 , Sep 8, 2017 |  BC Extra  |  Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $0.81 (12%) to $7.55 Thursday after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune...
17:09 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Adaptimmune starts Phase I of T cell therapy plus Keytruda

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial of NY-ESO SPEAR T-cell therapy (ADAP NY-ESO TCR, GSK3377794) plus Keytruda pembrolizumab to treat multiple myeloma (MM). The open-label, U.S. trial will evaluate safety in up to...
17:43 , May 5, 2017 |  BioCentury  |  Emerging Company Profile

Third cell’s the charm

Tactiva Therapeutics LLC is aiming to prolong the activity of TCR-based therapies by adding a third cell type that will act as a renewable source of the CD4+ cells necessary to sustain killer T cell...